What is the recommended dosage of Macrobid (nitrofurantoin monohydrate) for treating uncomplicated urinary tract infections (UTIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Macrobid (Nitrofurantoin Monohydrate) for Uncomplicated UTIs

The recommended dosage of Macrobid (nitrofurantoin monohydrate) for treating uncomplicated urinary tract infections is 100 mg twice daily for 5 days, as recommended by the Infectious Diseases Society of America and European Society for Microbiology and Infectious Diseases. 1

Dosing Regimen Details

  • Dosage: 100 mg twice daily
  • Duration: 5 days
  • Patient population: Adults with uncomplicated UTIs

Efficacy Evidence

Nitrofurantoin has demonstrated strong efficacy in treating uncomplicated UTIs:

  • In a 2018 randomized clinical trial, 5-day nitrofurantoin (100 mg three times daily) achieved clinical resolution in 70% of patients compared to 58% with single-dose fosfomycin, showing a significant advantage (difference of 12%, p=0.004) 2
  • Microbiological resolution was also superior with nitrofurantoin (74% vs 63%, p=0.04) 2
  • Earlier research from 2002 demonstrated that nitrofurantoin (100 mg four times daily for 3 days) was significantly more effective than placebo for both symptomatic relief and bacteriological cure 3

Special Populations and Contraindications

Renal Function Considerations

  • Important contraindication: Nitrofurantoin should be avoided in patients with renal impairment (GFR <30 ml/min) due to reduced efficacy and increased risk of toxicity 1
  • However, some evidence suggests nitrofurantoin may still be effective in patients with moderate renal insufficiency (CrCl 30-60 ml/min) 4

Pregnancy

  • Nitrofurantoin 100 mg twice daily for 5-7 days can be used in pregnant women with normal renal function 1
  • Important warning: Avoid in the third trimester of pregnancy due to risk of hemolytic anemia in newborns 1

Elderly Patients

  • Use with caution in elderly patients due to potential pulmonary and hepatic toxicity, though serious adverse events are rare (pulmonary toxicity 0.001%, hepatic toxicity 0.0003%) 1

Monitoring and Follow-up

  • Evaluate clinical response within 48-72 hours of initiating therapy 1
  • No routine follow-up urine culture is needed in patients who respond to therapy 1
  • A follow-up urine culture should be performed 7 days after completing treatment to assess for persistent or recurrent bacteriuria 1

Common Side Effects

  • Primarily gastrointestinal effects:
    • Nausea (approximately 3% of patients)
    • Diarrhea (approximately 1% of patients) 2

Clinical Pearls

  • Nitrofurantoin is considered a first-line agent for uncomplicated UTIs alongside trimethoprim-sulfamethoxazole and fosfomycin 5
  • While some UK guidelines recommend 3-day courses of nitrofurantoin, there is limited direct evidence supporting this shorter duration 6
  • The 5-day regimen has more robust evidence supporting its efficacy 2
  • Nitrofurantoin is not effective against Proteus species and other intrinsically resistant uropathogens 4
  • Efficacy may be reduced in alkaline urine 4

References

Guideline

Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2002

Research

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017

Research

Nitrofurantoin: what is the evidence for current UK guidance?

The Journal of antimicrobial chemotherapy, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.